Recent Updates
Recently added Catalysts
CRIS Positive Sentiment

Clinical Outcomes of Emavusertib Added to Azacitidine and Venetoclax Combination Therapy ASH 2025

Tuesday, December 9, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the clinical outcomes of Emavusertib when added to azacitidine and venetoclax combination therapy. This combination aims to enhance treatment efficacy for patients. The ongoing studies under the TakeAim program are highlighted, showcasing the potential benefits of this therapy in specific patient populations.
Price reaction · baseline $27 (2025-12-08 close) · hit pre-market · clean, no other CRIS news in the window
day 0 close
-1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Emavusertib shows potential when combined with azacitidine and venetoclax.
  • The combination therapy may improve clinical outcomes for patients.
  • Research indicates promising results in ongoing studies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What is Emavusertib?

Emavusertib is a drug being studied for its effectiveness in combination therapies.

What therapies is Emavusertib combined with?

It is combined with azacitidine and venetoclax in ongoing studies.

What is the goal of the TakeAim program?

The TakeAim program aims to improve treatment outcomes for specific patient populations.

Are there any reported benefits of this combination therapy?

Yes, the combination therapy shows promising results in enhancing clinical outcomes.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Emavusertib azacitidine venetoclax clinical outcomes
Last updated: Dec 9, 2025

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →